Skip to main content
SpringerLink
Log in

Camptothecins in Cancer Therapy

  • Book
  • © 2005

Overview

Editors:
  1. Val R. Adams

    1. Department of Pharmacy Practice and Science, College of Pharmacy, University of Kentucky, Lexington

    View editor publications

    You can also search for this editor in PubMed   Google Scholar

  2. Thomas G. Burke

    1. Department of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky, Lexington
      Experimental Therapeutics Program, Lucille P. Markey Cancer Center, University of Kentucky Medical Center, University of Kentucky, Lexington
      Tigen Pharmaceuticals Inc., Lexington

    View editor publications

    You can also search for this editor in PubMed   Google Scholar

Part of the book series: Cancer Drug Discovery and Development (CDD&D)

This is a preview of subscription content, log in via an institution to check access.

Access this book

Log in via an institution
eBook USD 169.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book USD 249.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Other ways to access

Licence this eBook for your library

Institutional subscriptions

Table of contents (17 chapters)

  1. Front Matter

    Pages i-xiii
    Download chapter PDF

  2. Biochemistry, Pharmacology, and Chemistry

    1. Front Matter

      Pages 1-1
      Download chapter PDF

    2. Mechanism of Action of Topoisomerase 1 Poisons

      • Leroy F. Liu, Shyamal D. Desai
      Pages 3-21

    3. Crystallographic Insight Into the Mechanism of Drug-Induced Topoisomerase I DNA Damage

      • Alex B. Burgin Jr., Michael D. Feese, Bart L. Staker, Lance Stewart
      Pages 23-38

    4. Inhibitors of Topoisomerase I Function

      • Sidney M. Hecht
      Pages 39-59

    5. Cytotoxic Mechanisms of Topoisomerase 1 Inhibitors

      • Yves G. Pommier, Juana Barceló, Takahisa Furuta, Haruyuki Takemura, Olivier Sordet, ZhiYong Liao
      Pages 61-107

    6. Biochemical and Genetic Analyses of DNA Topoisomerase 1-Mediated DNA Damage

      • Robert C. A. M. van Waardenburg, Mary-Ann Bjornsti
      Pages 109-125

    7. Preclinical Models for Evaluating Topoisomerase I-Targeted Drugs

      • Aarti S. Juvekar, Joyce Thompson, Clinton F. Stewart, Peter J. Houghton
      Pages 127-151

    8. Mechanisms of Resistance to Camptothecins

      • Zeshaan A. Rasheed, Eric H. Rubin
      Pages 153-169

    9. Recent Advances in Camptothecin Drug Design and Delivery Strategies

      • Thomas G. Burke, Tian-Xiang Xiang, Bradley D. Anderson, Lori J. Latus
      Pages 171-190

  3. Clinical Perspectives

    1. Front Matter

      Pages 191-191
      Download chapter PDF

    2. Clinical Experience With 9-Aminocamptothecin

      • Chris H. Takimoto
      Pages 193-206

    3. Clinical Studies of Rubitecan (9-Nitro 20(S) Camptothecin)

      • Hilary Hewes, Judith A. Smith, Claire Verschraegen
      Pages 207-228

    4. Irinotecan

      • Laurent P. Rivory
      Pages 229-262

    5. Clinical Experience With Topotecan

      • Aimee K. Bence, Val R. Adams
      Pages 263-299

    6. The Clinical Development of Lurtotecan

      • Keith T. Flaherty, James P. Stevenson, Christopher J. Twelves, Peter J. O’Dwyer
      Pages 301-316

    7. Preclinical and Clinical Development of Exatecan (DX-951f)

      • Eric K. Rowinsky
      Pages 317-341

    8. Camptothecins in the Treatment of Primary Brain Tumors

      • Clinton F. Stewart, Markos Leggas, Henry S. Friedman
      Pages 343-367

    9. Camptothecins in the Treatment of Lung Cancer

      • Pankaj Kumar, Missak Haigentz Jr., Jorge Gomez, Roman Perez-Soler
      Pages 369-419

    10. Use of Camptothecins in the Treatment of Leukemia and Related Disorders

      • Benjamin M. F. Mow, Scott H. Kaufmann
      Pages 421-450
Back to top

Keywords

About this book

A critical review our current understanding of camptothecins, their shortcomings, and of the possibilities for improving their clinical performance. The authors discuss new camptothecin analog development, drug delivery issues for optimizing their anticancer activity, and their potential use in a variety of different cancers. Additional chapters describe what is known about the biochemistry, the pharmacology, and the chemistry of the camptothecins, including the mechanism of topoisomerase and how camptothecins poison this enzyme, the use of animal models in defining the anticancer potential of camptothecins, and the question of camptothecin resistance.

Reviews

"...an excellent all-around reference appropriate for researchers or clinicians in anticancer drug literature." - Doody's Health Science Book Review Journal

Editors and Affiliations

  • Department of Pharmacy Practice and Science, College of Pharmacy, University of Kentucky, Lexington

    Val R. Adams

  • Department of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky, Lexington

    Thomas G. Burke

  • Experimental Therapeutics Program, Lucille P. Markey Cancer Center, University of Kentucky Medical Center, University of Kentucky, Lexington

    Thomas G. Burke

  • Tigen Pharmaceuticals Inc., Lexington

    Thomas G. Burke

Bibliographic Information

  • Book Title: Camptothecins in Cancer Therapy

  • Editors: Val R. Adams, Thomas G. Burke

  • Series Title: Cancer Drug Discovery and Development

  • DOI: https://doi.org/10.1385/1592598668

  • Publisher: Humana Totowa, NJ

  • eBook Packages: Medicine, Medicine (R0)

  • Copyright Information: Humana Press 2005

  • Hardcover ISBN: 978-1-58829-027-4Published: 01 February 2005

  • Softcover ISBN: 978-1-62703-816-4Published: 15 November 2014

  • eBook ISBN: 978-1-59259-866-3Published: 27 October 2007

  • Series ISSN: 2196-9906

  • Series E-ISSN: 2196-9914

  • Edition Number: 1

  • Number of Pages: XIII, 460

  • Topics: Oncology

Publish with us

Policies and ethics

Back to top

Search

Navigation